

Selective Serotonin Reuptake Inhibitors (SSRIs) (12)

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

AL – Age Limit	DD – Drug-Drug Interaction	MD – Maximum Dose Limit	TD - Therapeutic Duplication
BH – Behavioral Health Clinical Authorization for Children Younger than <u>76</u> Years of Age	DS Maximum Days’ Supply Allowed	PR – Enrollment in a Physician-Supervised Program Required	UN – Drug Use Not Warranted
BY – Diagnosis Codes Bypass Some Requirements	DT – Duration of Therapy Limit	PU – Prior Use of Other Medication is Required	X – Prescriber Must Have ‘X’ DEA Number
CL – Additional Clinical Information is Required	DX – Diagnosis Code Requirement	QL – Quantity Limit	YQ – Yearly Quantity Limit
CU – Concurrent Use with Other Medication is Restricted	ER – Early Refill	RX – Specific Prescription Requirement	

Pharmacy Prior Authorization Phone Numbers for MCOs and FFS

Aetna Better Health of Louisiana **1-855-242-0802**
 AmeriHealth Caritas Louisiana **1-800-684-5502**
 Fee-for-Service (FFS) Louisiana Legacy Medicaid **1-866-730-4357**
 Healthy Blue **1-844-521-6942**
 Louisiana Healthcare Connections **1-888-929-3790**
 UnitedHealthcare **1-800-310-6826**

Depression – Selective Serotonin Reuptake Inhibitors (SSRIs) (12)

POS Edits

BH – Additional behavioral-health related clinical information (trial of behavioral therapy, etc.) is required for all agents when requested for recipients who are younger than 76 years of age.

DX – Pharmacy claims for paroxetine (Brisdelle®) must be submitted with an appropriate diagnosis code for moderate-to-severe vasomotor symptoms associated with menopause (E28.310, E89.41, N95.1).

TD – These agents are monitored at the pharmacy POS for duplication of therapy with other SSRIs.

Revision	Date
Created POS Document	February 2020
<u>Modified to apply new age requirement for behavioral health clinical authorization</u>	<u>September 2020</u>